Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 12.5 mg (equivalent: perampanel, qty 12 mg) - tablet, film coated - excipient ingredients: hypromellose; povidone; microcrystalline cellulose; indigo carmine aluminium lake; purified talc; magnesium stearate; lactose monohydrate; macrogol 8000; titanium dioxide - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 2.1 mg (equivalent: perampanel, qty 2 mg) - tablet, film coated - excipient ingredients: purified talc; iron oxide red; iron oxide yellow; titanium dioxide; macrogol 8000; hypromellose; lactose monohydrate; magnesium stearate; povidone - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 6.2 mg (equivalent: perampanel, qty 6 mg) - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 8000; hypromellose; purified talc; lactose monohydrate; microcrystalline cellulose; iron oxide red; magnesium stearate; povidone - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 8.3 mg (equivalent: perampanel, qty 8 mg) - tablet, film coated - excipient ingredients: purified talc; macrogol 8000; iron oxide red; iron oxide black; povidone; hypromellose; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; colloidal anhydrous silica; magnesium stearate; crospovidone; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hyprolose; colloidal anhydrous silica; crospovidone; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin; indigo carmine aluminium lake - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; lecithin; indigo carmine aluminium lake - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; hyprolose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin; indigo carmine aluminium lake - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; hyprolose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.